Sarah M. Schroeder

Sarah M. Schroeder

Auto-generated profile, based on publicly available information

Sarah M. Schroeder

Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2022 in Science Immunology
Verified
Journal Article
Open access
YMYacine Maringer
Yacine Maringer
ANAnnika Nelde
Annika Nelde
SSSarah M. Schroeder
Sarah M. Schroeder
JSJuliane Schuhmacher
Juliane Schuhmacher
SHSebastian Hörber
Sebastian Hörber
JWJuliane S. Walz
Juliane S. Walz
Several COVID-19 vaccines are approved to prevent severe disease outcome after SARS-CoV-2 infection. Whereas induction and functionality of antiviral antibody response are largely studied, the induction of T cells upon vaccination with the different approved COVID-19 vaccines is less studied. Here, we report on T cell immunity 4 weeks and 6 months after different vaccination regimens and 4 weeks after an additional booster vaccination in comparison with SARS-CoV-2 T cell responses in convalescents and prepandemic donors using interferon-gamma ELISpot assays and flow cytometry. Increased T cell responses and cross-recognition of B.1.1.529 Omicron variant–specific mutations were observed ex vivo in mRNA- and heterologous-vaccinated donors compared with vector-vaccinated donors. Nevertheless, potent expandability of T cells targeting the spike protein was observed for all vaccination regimens, with frequency, diversity, and the ability to produce several cytokines of vaccine-induced T cell responses comparable with those in convalescent donors. T cell responses for all vaccinated donors significantly exceeded preexisting cross-reactive T cell responses in prepandemic donors. Booster vaccination led to a significant increase in anti-spike IgG responses, which showed a marked decline 6 months after complete vaccination. In contrast, T cell responses remained stable over time after complete vaccination with no significant effect of booster vaccination on T cell responses and cross-recognition of Omicron BA.1 and BA.2 mutations. This suggested that booster vaccination is of particular relevance for the amelioration of antibody response. Together, our work shows that different vaccination regimens induce broad and long-lasting spike-specific CD4 + and CD8 + T cell immunity to SARS-CoV-2.

17 November 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
NGNaomi Hoenisch Gravel
Naomi Hoenisch Gravel
ANAnnika Nelde
Annika Nelde
JBJens Bauer
Jens Bauer
LMLena Mühlenbruch
Lena Mühlenbruch
SSSarah M. Schroeder
Sarah M. Schroeder
JWJuliane S. Walz
Juliane S. Walz
T cell recognition of human leukocyte antigen (HLA)-presented tumor-associated peptides is central for cancer immune surveillance. Mass spectrometry (MS)-based immunopeptidomics represents the only unbiased method for the direct identification and characterization of naturally presented tumor-associated peptides, a key prerequisite for the development of T cell-based immunotherapies. This study reports on the implementation of ion mobility separation-based time-of-flight (TOFIMS) MS for next-generation immunopeptidomics, enabling high-speed and sensitive detection of HLA-presented peptides. Applying TOFIMS-based immunopeptidomics, a novel extensive benignTOFIMS dataset was generated from 94 primary benign samples of solid tissue and hematological origin, which enabled the expansion of benign reference immunopeptidome databases with > 150,000 HLA-presented peptides, the refinement of previously described tumor antigens, as well as the identification of frequently presented self antigens and not yet described tumor antigens comprising low abundant mutation-derived neoepitopes that might serve as targets for future cancer immunotherapy development.

17 October 2023 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
ANAnnika Nelde
Annika Nelde
HSHeiko Schuster
Heiko Schuster
JHJonas S. Heitmann
Jonas S. Heitmann
JBJens Bauer
Jens Bauer
YMYacine Maringer
Yacine Maringer
JWJuliane S. Walz
Juliane S. Walz
Therapy-resistant leukemia stem and progenitor cells (LSC) are a main cause of acute myeloid leukemia (AML) relapse. LSC-targeting therapies may thus improve outcome of patients with AML. Here we demonstrate that LSCs present HLA-restricted antigens that induce T-cell responses allowing for immune surveillance of AML. Using a mass spectrometry–based immunopeptidomics approach, we characterized the antigenic landscape of patient LSCs and identified AML- and AML/LSC-associated HLA-presented antigens absent from normal tissues comprising nonmutated peptides, cryptic neoepitopes, and neoepitopes of common AML driver mutations of NPM1 and IDH2. Functional relevance of shared AML/LSC antigens is illustrated by presence of their cognizant memory T cells in patients. Antigen-specific T-cell recognition and HLA class II immunopeptidome diversity correlated with clinical outcome. Together, these antigens shared among AML and LSCs represent prime targets for T cell–based therapies with potential of eliminating residual LSCs in patients with AML. Significance: The elimination of therapy-resistant leukemia stem and progenitor cells (LSC) remains a major challenge in the treatment of AML. This study identifies and functionally validates LSC-associated HLA class I and HLA class II–presented antigens, paving the way to the development of LSC-directed T cell–based immunotherapeutic approaches for patients with AML. See related commentary by Ritz, p. 430 . This article is featured in Selected Articles from This Issue, p. 419

18 August 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JHJonas S. Heitmann
Jonas S. Heitmann
CTClaudia Tandler
Claudia Tandler
MMMaddalena Marconato
Maddalena Marconato
ANAnnika Nelde
Annika Nelde
THTimorshah Habibzada
Timorshah Habibzada
JWJuliane S. Walz
Juliane S. Walz
T-cell immunity is central for control of COVID-19, particularly in patients incapable of mounting antibody responses. CoVac-1 is a peptide-based T-cell activator composed of SARS-CoV-2 epitopes with documented favorable safety profile and efficacy in terms of SARS-CoV-2-specific T-cell response. We here report a Phase I/II open-label trial (NCT04954469) in 54 patients with congenital or acquired B-cell deficiency receiving one subcutaneous CoVac-1 dose. Immunogenicity in terms of CoVac-1-induced T-cell responses and safety are the primary and secondary endpoints, respectively. No serious or grade 4 CoVac-1-related adverse events have been observed. Expected local granuloma formation has been observed in 94% of study subjects, whereas systemic reactogenicity has been mild or absent. SARS-CoV-2-specific T-cell responses have been induced in 86% of patients and are directed to multiple CoVac-1 peptides, not affected by any current Omicron variants and mediated by multifunctional T-helper 1 CD4+ T cells. CoVac-1-induced T-cell responses have exceeded those directed to the spike protein after mRNA-based vaccination of B-cell deficient patients and immunocompetent COVID-19 convalescents with and without seroconversion. Overall, our data show that CoVac-1 induces broad and potent T-cell responses in patients with B-cell/antibody deficiency with a favorable safety profile, which warrants advancement to pivotal Phase III safety and efficacy evaluation. ClinicalTrials.gov identifier NCT04954469.

29 December 2023 in Cancers
Verified
Journal Article
Open access
PDF file
CÖCansu Ebru Önder
Cansu Ebru Önder
MMMoustafa Moustafa-Oglou
Moustafa Moustafa-Oglou
SSSarah M. Schröder
Sarah M. Schröder
AHAndreas Hartkopf
Andreas Hartkopf
AKAndré Koch
André Koch
CSChristian Seitz
Christian Seitz
A frequent symptom of metastasized breast cancer (BC) includes the development of malignant pleural effusion (MPE), which contains malignant cells derived from the primary tumor site. The poor prognosis of MPE in metastasized BC indicates the necessity for dependable precision oncology and the importance of models representing the heterogenous nature of metastatic BC. In this study, we cultured MPE-derived metastatic tumor cells from four advanced BC patients using organoid technology. We assessed the expression of tumor-associated antigens on MPE-derived organoid lines by flow cytometry (FC). Based on an individual antigen expression pattern, patient-derived organoids were treated with adapter CAR-T cells (AdCAR-T) and biotinylated monoclonal antibodies targeting CD276, HER2, EGFR, TROP2, or EpCAM. Co-culture assays revealed specific organoid lysis by AdCAR-T depending on individual antigen expression patterns. Our results demonstrate that MPE-derived organoids can serve as a reliable tool for assessing the efficacy of AdCAR-T on metastatic BC in a patient-individualized manner. This approach could potentially be applied in a preclinical setting to instruct therapy decisions. Further, our study demonstrates the feasibility of precision immunotherapy utilizing AdCAR-T to target patient-individualized antigen patterns.

13 March 2026 in Cancer Medicine
Verified
Journal Article
Open access
JVJ. M. Vahl
J. M. Vahl
JHJ. Hahn
J. Hahn
AWA. von Witzleben
A. von Witzleben
SSS. M. Schroeder
S. M. Schroeder
CIC. Idel
C. Idel
SLS. Laban
S. Laban
Purpose: The prognostic relevance of gender in head and neck cancer is often neglected. In contrast, the more favorable prognosis of human papillomavirus (HPV)‐associated oropharyngeal squamous cell carcinoma (OPSCC) is well recognized, and de‐escalation strategies are increasingly being tested in clinical trials. In this study, we focused on the prognostic significance of gender to clarify whether it should be given more attention. Patients and Methods: We requested data on patients with newly diagnosed head and neck cancer between 2002 and 2017 from the German Center of Cancer Registry ( n = 212,920). First, we focused on sex‐specific survival according to primary tumor site in a nationwide context. Second, we examined a local dataset of 462 OPSCC patients, diagnosed at the University Hospitals of Ulm and Lübeck between 2005 and 2018 and followed up until 2024. Here we compared the prognostic value of sex with HPV status, alcohol consumption, and smoking habits (these parameters were not available at national level). Results: In the nationwide analysis, women showed better survival in all head and neck primary tumor sites studied. The mean survival difference was greatest in patients with OPSCC (1.3 years; p < 0.0001), followed by patients with nasopharyngeal carcinoma (1 year; p < 0.0001). In the subgroup of patients younger than the median age (62.8 years), women lived on mean 1.2 times longer than men ( p < 0.0001). Besides, in the local dataset, men with HPV‐positive OPSCC did not have a better prognosis than women, even when HPV‐negative ( p = 0.426). However, the prognostic effect of female sex may be attenuated in patients with high tobacco use; in this scenario, no sex‐related difference in survival was found ( p = 0.56). Conclusion: Sex‐specific differences in survival, especially in OPSCC and nasopharyngeal cancers, suggest the implementation of gender‐sensitive oncology regarding prevention, treatment, and aftercare.